Found 5 results
Author Title [ Type(Desc)] Year
Filters: Author is Heldman, Alan W  [Clear All Filters]
Journal Article
V. Karantalis, DiFede, D. L., Gerstenblith, G., Pham, S., Symes, J., Zambrano, J. Pablo, Fishman, J., Pattany, P., McNiece, I., Conte, J., Schulman, S., Wu, K., Shah, A., Breton, E., Davis-Sproul, J., Schwarz, R., Feigenbaum, G., Mushtaq, M., Suncion, V. Y., Lardo, A. C., Borrello, I., Mendizabal, A., Karas, T. Z., Byrnes, J., Lowery, M., Heldman, A. W., and Hare, J. M., “Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Ce”, Circ Res, vol. 114, no. 8, pp. 1302-10, 2014.
J. M. Hare, Fishman, J. E., Gerstenblith, G., Velazquez, D. L. DiFede, Zambrano, J. P., Suncion, V. Y., Tracy, M., Ghersin, E., Johnston, P. V., Brinker, J. A., Breton, E., Davis-Sproul, J., Schulman, I. H., Byrnes, J., Mendizabal, A. M., Lowery, M. H., Rouy, D., Altman, P., Foo, C. Wong Po, Ruiz, P., Amador, A., Da Silva, J., McNiece, I. K., Heldman, A. W., George, R., and Lardo, A., “Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.”, JAMA, vol. 308, no. 22, pp. 2369-79, 2012.
V. Y. Suncion, Ghersin, E., Fishman, J. E., Zambrano, J. Pablo, Karantalis, V., Mandel, N., Nelson, K. H., Gerstenblith, G., Velazquez, D. L. DiFede, Breton, E., Sitammagari, K., Schulman, I. H., Taldone, S. N., Williams, A. R., Sanina, C., Johnston, P. V., Brinker, J., Altman, P., Mushtaq, M., Trachtenberg, B., Mendizabal, A. M., Tracy, M., Da Silva, J., McNiece, I. K., Lardo, A. C., George, R. T., Hare, J. M., and Heldman, A. W., “Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial.”, Circ Res, vol. 114, no. 8, pp. 1292-301, 2014.
J. M. Hare, DiFede, D. L., Rieger, A. C., Florea, V., Landin, A. M., El-Khorazaty, J., Khan, A., Mushtaq, M., Lowery, M. H., Byrnes, J. J., Hendel, R. C., Cohen, M. G., Alfonso, C. E., Valasaki, K., Pujol, M. V., Golpanian, S., Ghersin, E., Fishman, J. E., Pattany, P., Gomes, S. A., Delgado, C., Miki, R., Abuzeid, F., Vidro-Casiano, M., Premer, C., Medina, A., Porras, V., Hatzistergos, K. E., Anderson, E., Mendizabal, A., Mitrani, R., and Heldman, A. W., “Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.”, J Am Coll Cardiol, vol. 69, no. 5, pp. 526-537, 2017.
B. Trachtenberg, Velazquez, D. L., Williams, A. R., McNiece, I., Fishman, J., Nguyen, K., Rouy, D., Altman, P., Schwarz, R., Mendizabal, A., Oskouei, B., Byrnes, J., Soto, V., Tracy, M., Zambrano, J. Pablo, Heldman, A. W., and Hare, J. M., “Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind”, Am Heart J, vol. 161, no. 3, pp. 487-93, 2011.